Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,269.00
Bid: 7,269.00
Ask: 7,270.00
Change: 40.00 (0.55%)
Spread: 1.00 (0.01%)
Open: 7,260.00
High: 7,279.00
Low: 7,209.00
Yest. Close: 7,229.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AstraZeneca's anifrolumab succeeds in lupus study

Tue, 12th Nov 2019 08:05

(Sharecast News) - Biopharmaceutical giant AstraZeneca's anifrolumab demonstrated superiority across multiple efficacy endpoints versus placebos in the drug's Phase III TULIP 2 trial.
AstraZeneca said anifrolumab achieved a "statistically significant and clinically meaningful reduction" in the treatment of moderate to severe systemic lupus erythematosus at the end of the 52-week trial, with 47.8% of patients receiving the drug responding favourably, compared with 31.5% of patients on a placebo.

The FTSE 100 resident also noted the TULIP 2 trial showed statistically significant differences in multiple secondary endpoints, with 51.5% of anifrolumab patients receiving oral corticosteroids greater than or equal to 10.0mg achieving a sustained reduction in OCS.

Additionally, 49% of patients receiving anifrolumab with moderate to severe skin disease experienced improved skin manifestations at week 12, the pre-specified timepoint.

Mene Pangalos, AstraZeneca's vice president of biopharmaceuticals research and development, said: "There has only been one new medicine approved for systemic lupus erythematosus in the last 60 years, which is why we are so excited to see the positive TULIP 2 results.

"There is now a strong body of evidence demonstrating the benefit of anifrolumab, and we look forward to bringing this potential new medicine to patients with systemic lupus erythematosus as soon as possible."

As of 0845 GMT, AstraZeneca shares were down 0.15% at 7,237p.

More News

AstraZeneca, Merck Get Marketing Authorization In China For Lynparza

AstraZeneca, Merck Get Marketing Authorization In China For Lynparza

5 Dec 19 08:31

AstraZeneca's Lynparza approved for use in China

(Sharecast News) - Biopharmaceutical company AstraZeneca announced on Thursday that Lynparza had been approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.

5 Dec 19 08:27

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

Dec 5 (Reuters) - AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.The approval in China is based on the results from a late-stage study in ...

5 Dec 19 07:11

REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

(Corrects typo in the first paragraph)Dec 5 (Reuters) - AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.The approval in China is based on th...

5 Dec 19 07:11

AstraZeneca Divests North American Seroquel and Seroquel XR Rights

AstraZeneca Divests North American Seroquel and Seroquel XR Rights

3 Dec 19 08:47

AstraZeneca sells Seroquel rights in US and Canada

(Sharecast News) - AstraZeneca has agreed to sell the commercial rights to 'Seroquel' - quetiapine fumarate immediate release - and 'Seroquel XR' - quetiapine fumarate extended release - in the United States and Canada to Cheplapharm Arzneimittel, it announced on Tuesday.

3 Dec 19 07:29

China to use drug bulk-buy program to close price gap

BEIJING, Nov 30 (Reuters) - China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.The move could force international drugmakers to...

30 Nov 19 15:47

TOP NEWS: AstraZeneca's Imfinzi Gains Priority Review From US FDA

TOP NEWS: AstraZeneca's Imfinzi Gains Priority Review From US FDA

29 Nov 19 08:13

LONDON MARKET PRE-OPEN: Ocado Signs Deal In Japan; Reach Decline Slows

LONDON MARKET PRE-OPEN: Ocado Signs Deal In Japan; Reach Decline Slows

29 Nov 19 07:43

AstraZeneca Imfinzi treatment gets FDA priority review

(Sharecast News) - AstraZeneca said the US Food and Drug Administration had accepted a supplemental Biologics License Application (sBLA) and granted priority review for its Imfinzi treatment of patients with previously untreated extensive-stage small cell lung cancer.

29 Nov 19 07:05

UK BROKER RATINGS SUMMARY: Morgan Stanley Downgrades Rolls-Royce

UK BROKER RATINGS SUMMARY: Morgan Stanley Downgrades Rolls-Royce

27 Nov 19 09:27

AstraZeneca shares rise on early U.S. approval for leukaemia drug

FRANKFURT, Nov 22 (Reuters) - AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie.AstraZeneca said late on Thursday that the U.S...

22 Nov 19 15:04

UPDATE 2-FTSE enjoys best day since July; mid-caps gain for 4th week

* FTSE 100 up 1.2%, FTSE 250 up 0.6%* Indexes bounce back after 2 days of losses* Pound falls after PMI data, aids exporters* Mid-cap Hochschild Mining, Coats Group underperform (Adds news items, updates to closing prices)By Shashwat Awasthi and Yad...

22 Nov 19 10:09

LONDON MARKET OPEN: Promising Start Amid Blue-Chip Exec Changes

LONDON MARKET OPEN: Promising Start Amid Blue-Chip Exec Changes

22 Nov 19 08:52

US Approves AstraZeneca's Calquence In Chronic Lymphocytic Leukaemia

US Approves AstraZeneca's Calquence In Chronic Lymphocytic Leukaemia

21 Nov 19 18:40

Login to your account

Don't have an account? Click here to register.